Thursday, March 16, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

USAMRIID Reagents Sole Source for Diagnostic Assay Development

by Global Biodefense Staff
April 23, 2014

The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) intends to award a sole-source contract for streptavidin and antibody-labeled oligonucleotide reagents needed to support novel diagnostic assay development efforts of USAMRIID’s Diagnostic Systems Division.

The proposed vendor for the award is Solulink of San Diego, CA. A review of potential sources for labeled oligonucleotides was conducted. Although the review identified several firms that manufacture oligonucleotides, Solulink was determined to be uniquely qualified to meet current requirements.

The requirement for the labeled oligonucleotides originates from a USAMRIID funded research project designed to develop novel diagnostic assays that can simultaneously detect multiple agent-specific nucleic acid and protein in a sample using an instrument capable of detecting nucleic acids only. The experimental design of these assays requires a reproducible quality labeled oligonucleotide.

The oligo used are 70 to 75 nucleotides (nt) in length which is significantly longer than normal. Synthesis of such a long oligonucleotide and purification is extremely tricky, requiring a skill that is gained and maintained only through practice. Accuracy of synthesis must be demonstrated and purification must be complete in order to successfully label the oligo.

While other companies can synthesize oligo’s, they do not routinely synthesize ones that are 75 nt’s in length. Very few companies have the ability and reputation of Solulink in synthesizing, purifying and then labeling 75 nt size oligos with both streptavidin and antibodies (separately but using the same oligo synthesis).

Source: FBO.gov, Solicitation Number: W81XWH-14-T-0133.

Related Posts

small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development
Industry News

DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development

January 10, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
Researcher holds a pipette
Biodetection

These Nanotech Bubbles Burst When They Detect Viruses in the Air

October 25, 2022
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC